L- and D-threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses

Heather K Knych, Dan S. McKemie, Kelsey Seminoff, Petra Hartmann, Lynn Hovda, Dionne Benson

Research output: Contribution to journalArticle

Abstract

Ethylphenidate is a psychostimulant and analog of the commonly prescribed compound, methylphenidate (Ritalin®). There are a limited number of studies describing the disposition and pharmacologic/toxicological effects of ethylphenidate in any species. The abuse potential in equine athletes along with the limited data available regarding administration in horses necessitates further study. The objectives of the current study were to describe drug concentrations, develop an analytical method that could be used to regulate its use, and describe the pharmacodynamic effects of ethylphenidate in horses. To that end, 12 horses were randomized into 3 dose groups (intravenous: 10 mg or 40 mg, oral: 40 mg). Ethylphenidate was administered and blood and urine samples were collected prior to and for up to 72 hours post drug administration. Concentrations of D-threo ethylphenidate and the metabolite ritalinic acid were measured using Liquid Chromatography–tandem Mass Spectrometry. L-threo ethylphenidate concentrations were estimated from D-threo ethylphenidate concentrations. Serum concentrations of ethylphenidate were below detectable levels by 8, 18, and 12 hours following intravenous administration of 10 mg and 40 mg and oral administration of 40 mg, respectively. Ritalinic acid was non-detectable at 72 hours in the group that received a 10-mg intravenous and 40-mg oral dose of ethylphenidate. Ritalinic acid concentrations were below the LOQ at 72 hours following intravenous administration of 40 mg of ethylphenidate. While the number of animals per dose group were small, no stimulatory behavior or significant changes in heart rate were noted. Untoward effects including gastrointestinal adverse effects were noted in all dose groups.

Original languageEnglish (US)
Pages (from-to)1508-1517
Number of pages10
JournalDrug Testing and Analysis
Volume10
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

ethylphenidate
Pharmacodynamics
Pharmacokinetics
horse
Horses
ritalinic acid
acid
drug
Methylphenidate
Intravenous Administration
urine
serum
analytical method
metabolite
mass spectrometry
blood
pharmacokinetics

Keywords

  • ethylphenidate
  • horse
  • pharmacokinetics
  • racing
  • ritalinic acid

ASJC Scopus subject areas

  • Analytical Chemistry
  • Environmental Chemistry
  • Pharmaceutical Science
  • Spectroscopy

Cite this

L- and D-threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses. / Knych, Heather K; McKemie, Dan S.; Seminoff, Kelsey; Hartmann, Petra; Hovda, Lynn; Benson, Dionne.

In: Drug Testing and Analysis, Vol. 10, No. 10, 01.10.2018, p. 1508-1517.

Research output: Contribution to journalArticle

Knych, Heather K ; McKemie, Dan S. ; Seminoff, Kelsey ; Hartmann, Petra ; Hovda, Lynn ; Benson, Dionne. / L- and D-threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses. In: Drug Testing and Analysis. 2018 ; Vol. 10, No. 10. pp. 1508-1517.
@article{22febcf0227442c9805eeabf66483835,
title = "L- and D-threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses",
abstract = "Ethylphenidate is a psychostimulant and analog of the commonly prescribed compound, methylphenidate (Ritalin{\circledR}). There are a limited number of studies describing the disposition and pharmacologic/toxicological effects of ethylphenidate in any species. The abuse potential in equine athletes along with the limited data available regarding administration in horses necessitates further study. The objectives of the current study were to describe drug concentrations, develop an analytical method that could be used to regulate its use, and describe the pharmacodynamic effects of ethylphenidate in horses. To that end, 12 horses were randomized into 3 dose groups (intravenous: 10 mg or 40 mg, oral: 40 mg). Ethylphenidate was administered and blood and urine samples were collected prior to and for up to 72 hours post drug administration. Concentrations of D-threo ethylphenidate and the metabolite ritalinic acid were measured using Liquid Chromatography–tandem Mass Spectrometry. L-threo ethylphenidate concentrations were estimated from D-threo ethylphenidate concentrations. Serum concentrations of ethylphenidate were below detectable levels by 8, 18, and 12 hours following intravenous administration of 10 mg and 40 mg and oral administration of 40 mg, respectively. Ritalinic acid was non-detectable at 72 hours in the group that received a 10-mg intravenous and 40-mg oral dose of ethylphenidate. Ritalinic acid concentrations were below the LOQ at 72 hours following intravenous administration of 40 mg of ethylphenidate. While the number of animals per dose group were small, no stimulatory behavior or significant changes in heart rate were noted. Untoward effects including gastrointestinal adverse effects were noted in all dose groups.",
keywords = "ethylphenidate, horse, pharmacokinetics, racing, ritalinic acid",
author = "Knych, {Heather K} and McKemie, {Dan S.} and Kelsey Seminoff and Petra Hartmann and Lynn Hovda and Dionne Benson",
year = "2018",
month = "10",
day = "1",
doi = "10.1002/dta.2408",
language = "English (US)",
volume = "10",
pages = "1508--1517",
journal = "Drug Testing and Analysis",
issn = "1942-7603",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - L- and D-threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses

AU - Knych, Heather K

AU - McKemie, Dan S.

AU - Seminoff, Kelsey

AU - Hartmann, Petra

AU - Hovda, Lynn

AU - Benson, Dionne

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Ethylphenidate is a psychostimulant and analog of the commonly prescribed compound, methylphenidate (Ritalin®). There are a limited number of studies describing the disposition and pharmacologic/toxicological effects of ethylphenidate in any species. The abuse potential in equine athletes along with the limited data available regarding administration in horses necessitates further study. The objectives of the current study were to describe drug concentrations, develop an analytical method that could be used to regulate its use, and describe the pharmacodynamic effects of ethylphenidate in horses. To that end, 12 horses were randomized into 3 dose groups (intravenous: 10 mg or 40 mg, oral: 40 mg). Ethylphenidate was administered and blood and urine samples were collected prior to and for up to 72 hours post drug administration. Concentrations of D-threo ethylphenidate and the metabolite ritalinic acid were measured using Liquid Chromatography–tandem Mass Spectrometry. L-threo ethylphenidate concentrations were estimated from D-threo ethylphenidate concentrations. Serum concentrations of ethylphenidate were below detectable levels by 8, 18, and 12 hours following intravenous administration of 10 mg and 40 mg and oral administration of 40 mg, respectively. Ritalinic acid was non-detectable at 72 hours in the group that received a 10-mg intravenous and 40-mg oral dose of ethylphenidate. Ritalinic acid concentrations were below the LOQ at 72 hours following intravenous administration of 40 mg of ethylphenidate. While the number of animals per dose group were small, no stimulatory behavior or significant changes in heart rate were noted. Untoward effects including gastrointestinal adverse effects were noted in all dose groups.

AB - Ethylphenidate is a psychostimulant and analog of the commonly prescribed compound, methylphenidate (Ritalin®). There are a limited number of studies describing the disposition and pharmacologic/toxicological effects of ethylphenidate in any species. The abuse potential in equine athletes along with the limited data available regarding administration in horses necessitates further study. The objectives of the current study were to describe drug concentrations, develop an analytical method that could be used to regulate its use, and describe the pharmacodynamic effects of ethylphenidate in horses. To that end, 12 horses were randomized into 3 dose groups (intravenous: 10 mg or 40 mg, oral: 40 mg). Ethylphenidate was administered and blood and urine samples were collected prior to and for up to 72 hours post drug administration. Concentrations of D-threo ethylphenidate and the metabolite ritalinic acid were measured using Liquid Chromatography–tandem Mass Spectrometry. L-threo ethylphenidate concentrations were estimated from D-threo ethylphenidate concentrations. Serum concentrations of ethylphenidate were below detectable levels by 8, 18, and 12 hours following intravenous administration of 10 mg and 40 mg and oral administration of 40 mg, respectively. Ritalinic acid was non-detectable at 72 hours in the group that received a 10-mg intravenous and 40-mg oral dose of ethylphenidate. Ritalinic acid concentrations were below the LOQ at 72 hours following intravenous administration of 40 mg of ethylphenidate. While the number of animals per dose group were small, no stimulatory behavior or significant changes in heart rate were noted. Untoward effects including gastrointestinal adverse effects were noted in all dose groups.

KW - ethylphenidate

KW - horse

KW - pharmacokinetics

KW - racing

KW - ritalinic acid

UR - http://www.scopus.com/inward/record.url?scp=85054910626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054910626&partnerID=8YFLogxK

U2 - 10.1002/dta.2408

DO - 10.1002/dta.2408

M3 - Article

VL - 10

SP - 1508

EP - 1517

JO - Drug Testing and Analysis

JF - Drug Testing and Analysis

SN - 1942-7603

IS - 10

ER -